Dr. Anatoly Belostotskii is affiliated to the Department of Chemistry , Bar Ilan University, where Dr. Anatoly Belostotskii is currently working as Professor. Dr. Anatoly Belostotskii has numerous publications within the specialty and published in reputed national and international peer-reviewed journals. Dr. Anatoly Belostotskii is actively associated with different national and international societies and academies. Dr. Anatoly Belostotskii gain recognition among the honourable subject experts with the contributions made. Dr. Anatoly Belostotskii is been appreciated by several reputed awards and funding support. Dr. Anatoly Belostotskii major research interest is in studies related to Structure, synthesis and drug-oriented design of small biomolecules are in the scope of my research. In structural studies, computational chemistry is main methodology, and my focus there has shifted from modeling of conformational dynamics to conformational analysis by means of a new (for synthetic chemists) tool in structure determination – QM-calculated chemical shifts. In synthetic studies, my main targets are DNA components, and my chemistry includes rational modifications of nucleoside structure in order to “equip” new nucleoside derivatives with a potent antiretroviral or anticancer activity. The goal chemical structures are prompted by my original design concepts; examples of the latter are agent-induced post-transriptional disruption of the nucleic acid chain and carbohydrate-mediated cryodeprotection. .

Structure, synthesis and drug-oriented design of small biomolecules are in the scope of my research. In structural studies, computational chemistry is main methodology, and my focus there has shifted from modeling of conformational dynamics to conformational analysis by means of a new (for synthetic chemists) tool in structure determination – QM-calculated chemical shifts. In synthetic studies, my main targets are DNA components, and my chemistry includes rational modifications of nucleoside structure in order to “equip” new nucleoside derivatives with a potent antiretroviral or anticancer activity. The goal chemical structures are prompted by my original design concepts; examples of the latter are agent-induced post-transriptional disruption of the nucleic acid chain and carbohydrate-mediated cryodeprotection.